A Critical Scoping Review of Extraoral Photobiomodulation for Oral Mucositis in Oncological Patients.
리뷰
1/5 보강
[AIMS] Oral mucositis (OM) is a potentially severe side effect of oncological treatment.
- 연구 설계 randomized controlled trial
APA
Monteiro JLGC, Martins MD, et al. (2026). A Critical Scoping Review of Extraoral Photobiomodulation for Oral Mucositis in Oncological Patients.. Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry, 46(1), e70145. https://doi.org/10.1111/scd.70145
MLA
Monteiro JLGC, et al.. "A Critical Scoping Review of Extraoral Photobiomodulation for Oral Mucositis in Oncological Patients.." Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry, vol. 46, no. 1, 2026, pp. e70145.
PMID
41715303 ↗
Abstract 한글 요약
[AIMS] Oral mucositis (OM) is a potentially severe side effect of oncological treatment. This study aimed to conduct a comprehensive scoping review of extraoral photobiomodulation (EOPBM) in the treatment or prevention of OM in oncologic patients. Studies were categorized according to the Oxford Centre for Evidence-Based Medicine (OCEBM) recommendations.
[METHODS] A search was conducted in three databases for comparative or non-comparative studies. There were no language or publication year restrictions.
[RESULTS] The review included nine studies, with varying levels of evidence. Three studies were categorized as OCEBM level 2, and six as level 4. While EOPBM offered advantages, such as shorter session durations and potentially more accessible light application, the review found limited evidence for its exclusive use in preventing or treating OM. It included a single randomized controlled trial (RCT) comparing EOPBM with IOPBM, which found no significant differences between the groups in OM development or severity. Additionally, studies comparing EOPBM with sham sessions, placebo, or no treatment yielded mixed results.
[CONCLUSIONS] EOPBM shows promise in preventing OM in oncological patients, with some advantages such as shorter session durations. However, the current level of evidence for exclusive EOPBM protocols remains limited.
[METHODS] A search was conducted in three databases for comparative or non-comparative studies. There were no language or publication year restrictions.
[RESULTS] The review included nine studies, with varying levels of evidence. Three studies were categorized as OCEBM level 2, and six as level 4. While EOPBM offered advantages, such as shorter session durations and potentially more accessible light application, the review found limited evidence for its exclusive use in preventing or treating OM. It included a single randomized controlled trial (RCT) comparing EOPBM with IOPBM, which found no significant differences between the groups in OM development or severity. Additionally, studies comparing EOPBM with sham sessions, placebo, or no treatment yielded mixed results.
[CONCLUSIONS] EOPBM shows promise in preventing OM in oncological patients, with some advantages such as shorter session durations. However, the current level of evidence for exclusive EOPBM protocols remains limited.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.